federal_register: 2020-28602
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-28602 | Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments | Notice | The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (BsUFA)" and an opportunity for public comment. The topics to be discussed are the interim assessment and public stakeholder views of the program to date. | 2020-12-28 | 2020 | 12 | https://www.federalregister.gov/documents/2020/12/28/2020-28602/interim-assessment-of-the-program-for-enhanced-review-transparency-and-communication-in-the | https://www.govinfo.gov/content/pkg/FR-2020-12-28/pdf/2020-28602.pdf | Health and Human Services Department; Food and Drug Administration | 221,199 | The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (BsUFA)" and an... |